Sarabjit Kour Nangra VP Research- Pharma Angel Broking P However, according to Surajit Pal of Prabhudas Lilladher the USFDA issue will lead to further big consultation costs which could eat up the margins going forward. Ranbaxy Laboratories, ... Moneycontrol.com, 1 month ago
Ranbaxy Labs gets USFDA 483's for its Toansa plant - Angel Broking - Equity Bulls, 1 month ago
2 images for "sarabjit kour nangra"
Mumbai-based pharma major Lupin, on Thursday, announced that it has received final approval from the US Food and Drug Administration (FDA) to market generic versions of Bayer's Cipro and Aqua Pharmaceuticals Monodox in the American market. Lupin ...Financial Chronicle, 1 day ago
Indian drug maker Dr Reddys has launched a generic and low priced version of the brand Avelox which is under marketing license with Merck. For the US market, the brand has total sales of $195 million at the end of one year in December 2013, estimates IMS ...The Financial Chronicle, 2 days ago
Regulatory concerns and adverse market conditions notwithstanding, the pharmaceutical industry in India continues to attract retail, as well as institutional investors and looks poised for growth in the coming years. By Usha Sharma In today's ...Express Pharma, 2 days ago
A file photograph of a stock broker at a brokerage firm in Mumbai.Reuters Parliamentary elections in India, the world's largest democracy, will commence on 7 April and some analysts expect a stock market rally in the run-up to the month-long ...International Business Times UK, 2 days ago Sanofi India shares up 3 per cent; m-cap surges by Rs 268 crore Economic Times, 1 week ago Sanofi India shares jumps over 5 pc on robust earnings Financial Express, 1 week ago Sanofi India stock jumps over 5% on robust earnings NDTV Profit, 1 week ago
More from: , Daily Excelsior.com...and 1 other sources
Shares of AstraZeneca Pharma India soared 20 per cent to hit the upper circuit on the BSE on Monday after the company announced a proposal to delist its shares from the Indian stock exchanges, but many dealers and traders are skeptical of the ...Topnews.in, 3 days ago 'Ukraine crisis won't hit Indian pharma cos severely' Economic Times, 3 days ago Analysts not hopeful of AstraZeneca Pharma delisting sailing through The Freepress Journal, 3 days ago
Ranbaxy Laboratories on Tuesday suspended all shipments of active pharmaceutical ingredients (APIs) produced at its Toansa and Dewas plants in order to enable it to review processes and controls. The two factories are currently banned from ...Financial Express, 1 week ago Ranbaxy Laboratories locked out of its biggest market with API shutdown Financial Express, 1 week ago
Shares of Ranbaxy Ltd on Tuesday fell over 2% on the bourses after the company said it has suspended shipments of all pharmaceutical ingredients from its Tonsa and Dewas plants. "This voluntary decision was taken as a precautionary measure and ...Hindustan Times, 1 week ago Ranbaxy Suspends Shipments From Two Plants Outlook India, 1 week ago Ranbaxy suspends shipments; falls over 2% Hindustan Times, 1 week ago Ranbaxy suspends shipments from 2 plants; shares down over 2% Rediff.com, 1 week ago
More from: , Hindustan Times...and 1 other sources
The Toansa and Dewas plants are currently banned from shipping products to United States following quality concerns, so the suspension will hit supplies to other markets including Europe and India, two people with knowledge of the matter said. The sources ...Jagran Post, 1 week ago Ranbaxy Lab suffers another setback as US FDA bans its 4th plant, shares slump 20% Financial Express, 1 month ago FDA Bans 4th Ranbaxy Plant, Halting Company's Exports to US New Indian Express, 1 month ago FDA bans Ranbaxy's Toansa plant, halting company's exports to US Financial Chronicle, 1 month ago
More from: , Outlook India...and 3 other sources
The US unit of Ranbaxy and US firm Teva Pharmaceutical Industries have settled a claim by the New York attorney general that an unlawful agreement between the two rival generic drugmakers restricted competition in the market. Under the terms of the ...The Financial Chronicle, 2 weeks ago Ranbaxy, Teva settle claims with New York AG Economic Times, 2 weeks ago Ranbaxy gains after settling with NY Attorney General over collusion Yahoo! UK and Ireland, 2 weeks ago Ranbaxy, Teva Settle With NY Attorney General Over Collusion Businessworld India, 2 weeks ago
on your WebpageAdd Widget >Get your members hooked!